Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients.
Chemotherapy
; 54(6): 421-4, 2008.
Article
em En
| MEDLINE
| ID: mdl-18824847
ABSTRACT
We report the clinical history of a female affected by advanced colorectal cancer (CRC). The patient was treated with five subsequent therapeutic schedules (FOLFIRI, FOLFOXIRI, FOLFIRI, FOLFOX4, FOLFOX4 plus cetuximab) because of the progression of the disease. The sixth treatment was bevacizumab in combination with 5-fluorouracil and irinotecan (FOLFIRI). The CT scan and the FDG-PET/CT performed 3 months after the beginning of the treatment showed that some, even if not all, lesions had a reduction of both size and metabolic activity. After the second revaluation the disease progressed. This short report suggests that the response of CRC to antiangiogenetic therapy may also occur after several unsuccessful antineoplastic treatments. Different biological features may explain the nonhomogeneous objective response of the metastatic lesions. Molecular imaging techniques seem to be mandatory in the era of tailored therapy since it is useful to have an in vivo 'biological picture' of the neoplastic disease.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Anticorpos Monoclonais
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Chemotherapy
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Itália